Data shows drug slowing Alzheimer’s but doubts over effect remain

Experts have welcomed full data showing an experimental drug can slow cognitive decline in Alzheimer's patients, but warned improvements were comparatively small and said it remained unclear how much difference it might make in people's lives. Japanese drugmaker Eisai and its United States partner Biogen announced in September that preliminary data from a trial of lecanemab found it slowed cognitive decline by 27 percent across 18 months. the companies on Tuesday provided the full results of the study on nearly 1,800 people in the earliest stages of the disease, the most common cause of dementia among older adults.

Al Jazeera's Harry Fawcett reports from London.

Subscribe to our channel: http://bit.ly/AJSubscribe Follow us on Twitter: https://twitter.com/AJEnglish Find us on Facebook: https://www.facebook.com/aljazeera Check our website: http://www.aljazeera.com/ Check out our Instagram page: https://www.instagram.com/aljazeeraenglish/

#Alzheimers #lecanemab #Biogen #Eisai